Skip to main content
. 2017 Jul 13;7:5303. doi: 10.1038/s41598-017-05525-4

Figure 8.

Figure 8

Cytotoxicity analysis of various doxorubicin formulations on ovarian cancer and normal cells. Viability of ovarian cancer OVCAR-3 (a), and normal 3T3 (b) cells. The HisHBcAg nanoparticles conjugated covalently with folic acid (FA) and non-covalently with NTA-DOX (FA-HisHBcAg-NTA-DOX) were more efficient in inhibiting the growth of OVCAR-3 cells compared to that of other formulations. On the other hand, this formulation (FA-HisHBcAg-NTA-DOX) was less toxic to normal 3T3 cells, resulted in a conferred protection of the normal cells from DOX. The HisHBcAg nanoparticles (HisHBcAg) were not toxic to both normal and cancer cells as shown in the small graphs on the right. Data represent mean ± SD of triplicate determinations.